Skip to content

Multi-omics integration for early Identification of pre-Chronic Obstructive Pulmonary Disease

Multi-omics integration for early Identification of pre-Chronic Obstructive Pulmonary Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121780
Enrollment
Unknown
Registered
2026-04-02
Start date
2026-04-02
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

pre-COPD:None

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age: 40–80 years; (2) Individuals with pre-COPD should meet the definition of pre-COPD: presence of chronic respiratory symptoms, structural lung abnormalities (emphysema), or respiratory physiological abnormalities (preserved ratio impaired lung function, reduced DLCO, or rapid decline in FEV1 over a short period), with a post-bronchodilator FEV1/FVC >= 0.7; individuals with COPD should have a post-bronchodilator FEV1/FVC < 0.7; (3) Agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Respiratory tract infection or acute exacerbation within 4 weeks prior to screening; (2) Cardiac events (myocardial infarction, malignant arrhythmia) within 3 months prior to screening; (3) Hospitalization due to heart disease within 1 month prior to screening; (4) Thoracic, abdominal, or ocular surgery within 3 months prior to screening; (5) Newly diagnosed and actively treated malignancy; (6) History of lobectomy; (7) Active pulmonary tuberculosis or currently taking anti-tuberculosis medications; (8) Mental disorders, visual hallucinations, auditory hallucinations, or use of antipsychotic medications; (9) Cognitive impairment, including dementia; (10) High-level paraplegia; (11) Pregnant or breastfeeding women; (12) BMI > 35 (to facilitate CT examination).

Design outcomes

Primary

MeasureTime frame
Spirometry pre- and post-bronchodilation;

Secondary

MeasureTime frame
Acute Exacerbation Assessment;

Countries

China

Contacts

Public ContactXin Chen

Zhujiang Hospital, Southern Medical University

chen_xin1020@163.com+86 139 0220 5193

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026